Current status and progress of perioperative treatment of esophageal cancer
JIANG Yubo
ZHAO Chuanhua
LI Shanshan
WANG Yan
XU Jianming
Abstract：Esophageal cancer is a highly lethal and aggressive gastrointestinal cancer nationwide. Esophageal squamous cell carcinoma(SCC) is endemic in Asian countries, while adenocarcinoma is more common in western countries. In China, SCC accounted for 95% of esophageal carcinoma. Surgery is the main treatment method for esophageal cancer. However, the results of surgery alone have been dissatisfactory, with survival rates of approximately 30% at 5 years. So, new combinations of different protocols have been investigated by many trials. According to accurate preoperative staging, stage Ⅰ and ⅡA esophageal cancer is suitable for direct sur?gery, while stage ⅡB and Ⅲ should be primarily treated with neoadjuvant chemotherapy or chemoradiation followed by surgery. Adju?vant treatment maybe helpful to improve the outcomes of patients, but it still needs further studies. Furthermore, molecular targeted therapy and predictors for neoadjuvant treatment are increasingly becoming research hotspots of esophageal cancer.
Keywords：Esophageal cancerPerioperative treatmentNeoadjuvant treatmentAdjuvant treatment
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 185-190 )